CDNA
CareDx, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$85.40
−3.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 497.4M | 379.8M | 333.8M | 280.3M | 321.8M |
| Cost of Revenue | 144.4M | 123.2M | 109.6M | 102.0M | 112.2M |
| Gross Profit | 353.0M | 256.6M | 224.2M | 178.3M | 209.6M |
| Operating Expenses | |||||
| R&D Expense | 84.4M | 71.4M | 72.4M | 81.9M | 90.4M |
| SG&A Expense | 264.5M | 210.2M | 205.5M | 201.2M | 196.4M |
| General & Admin Expense | 138.1M | 107.6M | 123.8M | 117.9M | 100.4M |
| Selling & Marketing Expense | 126.4M | 102.6M | 81.7M | 83.3M | 96.0M |
| Other Expenses | — | — | (94.5M) | 98.6M | — |
| Total Operating Expenses | 348.9M | 281.6M | 183.4M | 381.7M | 286.8M |
| Cost and Expenses | 493.3M | 404.9M | 293.0M | 483.7M | 399.0M |
| Operating Income (EBIT) | 4.1M | (25.1M) | 40.8M | (203.4M) | (77.2M) |
| Non-Operating | |||||
| Interest Income | 7.9M | 9.2M | 11.8M | 11.9M | 3.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 7.9M | 9.2M | 11.8M | 11.9M | 3.8M |
| Other Non-Op Income/Expense | 120.1M | 4.0M | 12.1M | 13.2M | 997.0K |
| Non-Operating Income (excl Interest) | (2.6M) | — | 94.5M | (98.6M) | (997.0K) |
| EBT (Pre-Tax Income) | 124.2M | (21.1M) | 52.9M | (190.1M) | (76.2M) |
| Income Tax Expense | (4.4M) | 271.0K | 310.0K | 141.0K | 379.0K |
| Bottom Line | |||||
| Net Income | 128.6M | (21.4M) | 52.5M | (190.3M) | (76.6M) |
| Earnings from Cont. Ops | 128.6M | (21.4M) | 52.5M | (190.3M) | (76.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 128.6M | (21.4M) | 52.5M | (190.3M) | (76.6M) |
| Per Share | |||||
| Basic EPS | $2.49 | ($0.40) | $1.00 | ($3.54) | ($1.44) |
| Diluted EPS | $2.39 | ($0.40) | $0.93 | ($3.54) | ($1.44) |
| Revenue Per Share | $9.54 | $7.13 | $6.32 | $5.21 | $6.03 |
| Shares | |||||
| Basic Shares Outstanding | 52.1M | 53.3M | 52.8M | 53.8M | 53.3M |
| Diluted Shares Outstanding | 55.0M | 53.3M | 56.6M | 53.8M | 53.3M |
| Profitability Metrics | |||||
| EBITDA | 28.5M | (4.7M) | (34.0M) | (84.9M) | (60.2M) |
| D&A | 21.8M | 20.4M | 19.8M | 19.8M | 16.0M |
| EBIT | 6.7M | (25.1M) | (53.8M) | (104.7M) | (76.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026